Category: Community Partners

HIV Care Services Quick Take

Posted on by DDP PR Coordinator

Ending CHARLII and Continuing Seamless Programs

View as PDF

Reintegrated persons (or persons reentering communities after leaving prisons & jails) should be referred to local community-based organizations (CBOs) and healthcare facilities providing medical & support services by the Department of Corrections (DoC) and some local & regional jails for HIV services including medication.

Setting the Stage for What’s Next: CHARLII & Seamless

The Comprehensive HIV/AIDS Resources and Linkages for Individuals experiencing Incarceration (CHARLII) program at the Virginia Department of Health (VDH) ended on June 30, 2025 due to the Ryan White Part B funding cuts. This program partnered with the VA Department of Corrections (DoC) and some local & regional jails to provide HIV medication and other services: medical case management (MCM), mental health (MH), Substance Use Disorder treatment (SUD tx), emergency financial assistance (EFA), and housing to inmates and those nearing reintegration.

As of July 1, 2025, reintegrated persons may access medication and other HIV services at your agencies through referral from the DoC and local & regional jails. Before the start of grant year 2025, many of these services were funded directly through the VDH Ryan White Part B grant that established a provider system of contracted agencies offering Health Resources and Services Administration (HRSA)-legislated core medical and support services to HIV patients in Virginia. Now and until further notice, services will be offered through Ryan White Part B-contracted agencies as well as non-Part B-contracted agencies.

Seamless Solution

Persons reintegrating from DoC and local prisons & jails may qualify for the Seamless program if they received less than 30 days of medication upon starting reintegration. This program provides 30 days of medication for agencies to honor previous referrals and conduct full unified eligibility assessments (UEAs) for other needed services or referrals to other community providers for needed services.

Action Steps

The VDH requests your continued assistance to integrate these persons into your current patient population and provide the quality services you have established for all patients you serve.

VDH Contacts

Kimberly Eley, VDH Medication Access Field Manager

    • 804-543-0122
    • kimberly.eley@vdh.virginia.gov

Rivkah Meder, VDH Care Services Field Manager

    • 804-235-1445
    • rebecca.meder@vdh.virginia.gov

Susan Carr, Special Projects Coordinator

    • 804-397-5056
    • susan.carr@vdh.virginia.gov

Virginia Ryan White Part B Resources

Posted on by DDP PR Coordinator

The Virginia Department of Health’s Division of Disease Prevention (DDP) has updated its website with a list of community-based care and treatment resources as well as provider and client FAQs (frequently asked questions).

This information may be helpful to clients, providers, and other stakeholders affected by recent changes in the program or for those who want more information.

Clients with questions can contact:

    • Any Ryan White Part B provider,
    • their case managers, or
    • the VDH Medication Eligibility Hotline: (855) 362-0658.

Direct press inquiries regarding Ryan White Services to the VDH Newsroom.

There’s a New PrEP Option!

Posted on by DDP PR Coordinator

Lenacapavir was approved by the Food and Drug Administration (FDA) on June 18 for use as HIV Pre-Exposure Prophylaxis (PrEP).  It is an injection given twice a year.  It will be sold under the brand name Yeztugo (yez-TOO-go).  Clinical trials proved the drug blocked HIV in 100% of >2,000 cisgender women who’d received it in the PURPOSE 1 trial.  The drug blocked HIV in nearly 100% of>2,000 cisgender men and gender-diverse persons who’d received it in the PURPOSE 2 trial.

Lenacapavir (Sunlenca) was approved for HIV treatment in 2022 for people with HIV.  This was specific to those with limited treatment options due to drug resistance, intolerance, or safety considerations.  Because it is a capsid inhibitor, the chance of developing drug resistance when taking it for PrEP is low.  Capsid inhibitors are a new class of medication not used in any other drugs currently.  Yeztugo’s price will be comparable to Apretude, the long-acting injectable which was approved for PrEP in 2021.

Providers: For more information, refer to the Gilead website or prescribing information. There is an upcoming training opportunity for clinicians to learn more on July 11.

Consumers: If you are interested in this new PrEP option, talk to your healthcare provider.

If you have any questions, please contact Eric Mayes, PrEP Services Coordinator, or Jenny Calhoun, HIV/STI Nurse Consultant.  Eric can be reached at eric.mayes@vdh.virginia.gov.  Jenny can be reached at jenny.calhoun@vdh.virginia.gov.

Virginia’s Hepatitis Elimination Plan

Posted on by DDP PR Coordinator

Hep Free VA

Cover of Hep Free VA, the Virginia Hepatitis Elimination Plan

Learn about Hep Free VA and help us end viral hepatitis in Virginia

Viral hepatitis is an ongoing and nationwide public health concern.  Last year in Virginia, reportable viral hepatitis cases were the third highest reportable condition1.  Only cases of chlamydia and gonorrhea were reported in greater number.  Untreated viral hepatitis can cause serious negative health outcomes.  This can include liver disease, liver cancer, and death.  However, vaccines and antiviral treatments can help to stop viral hepatitis.  Vaccinations are available to prevent hepatitis A and B.  Hepatitis C is now curable through a short course of direct acting antiviral treatments.

DDP has collaborated with a range of statewide stakeholders to create Hep Free VA.  This is Virginia’s Viral Hepatitis Elimination Plan.  The plan aims to eliminate viral hepatitis in Virginia by 2030 by achieving six main goals.

    • Goal 1: Prevent New Viral Hepatitis Infections
    • Goal 2: Improve Viral Hepatitis-Related Health Outcomes of People with Viral Hepatitis
    • Goal 3: Reduce Viral Hepatitis-Related Disparities
    • Goal 4: Improve Viral Hepatitis Surveillance and Data Usage
    • Goal 5: Achieve Integrated, Coordinated Efforts that Address the Viral Hepatitis Epidemics among All Partners and Stakeholders
    • Goal 6: Secure Sustainable Funding to Address Viral Hepatitis Epidemics

Read our full plan!

DDP is grateful to all the stakeholders and partners who joined us in this effort.  We look forward to continuing our viral hepatitis elimination work with you.

If you would like to get involved to end viral hepatitis in Virginia, please contact Colin Dwyer at colin.dwyer@vdh.virginia.gov or (804) 613-8228.

 

1 Virginia Department of Health. (n.d.).  Virginia Monthly Morbidity Surveillance Report.  https://www.vdh.virginia.gov/surveillance-and-investigation/virginia-communicable-disease-data/virginia-monthly-morbidity-surveillance-report-2018/